Gene therapy supplier MIP Discovery closes £7M Series A financing
The £7m Series A financing of British gene therapy vector specialist MIP Discovery Ltd was led by lMercia Ventures.Existing investor Calculus Capital...
Deregulation of new genomic techniques before decision
Although the required approval of 15 agriculture ministers was achieved in mid-December, the hotly debated proposal of the EU Commission to relax...
Researcher find potential target for atherosclerosis
Researchers have found a new way to reverse atherosclerotic plaque formation at the early stages. In Nature Cardiovascular Research, Alma...
PulseSight to disrupt AMD space
Aiming to address the pressing challenges of age-related macular diseases (AMD), including wet and dry AMD, along with geographic atrophy (GA),...
AstraZeneca to acquire Amolyt Pharma for up to US$1.05bn
Under the agreement set to close in Q3/2024, AstraZeneca will acquire Amolyt Pharma for US$800m upfront and potential milestone payments of US$250m....
Swiss vaccine developer Limma Tech get CARB-X grant
LimmaTech said, it will use the grant to advance preclinical development of its hexavalent vaccine candidate targeting Neisseria gonorrheae. Using...
Bayer SE secures rights to in €310m deal
Under the licence deal, BridgeBio Pharma, Inc. will pass the commercialisation rights for the transthyretin stabiliser acoramidis in Europe where...